Skip to main content
. 2018 Oct 11;2:22. doi: 10.22454/PRiMER.2018.493524

Table 3.

Key Conceptual Concerns

1. Does the benefit of pharmacogenomic testing outweigh the risk?
  • Benefits

    • “Laying it out there to see if this person has a genetic susceptibility to the medication [in] good or bad ways. It just helps you make a more informed decision.”

    • “We can essentially be better at our jobs.”

    • “…if the medicine is not helping the patient…then it’s at least helpful to go ahead and get the information and then change the medication accordingly.”

    • “It’s [going to] be better for the patient overall.”

    • “…to change what you’re giving [the patient] and…knowing there might be a reason why a [medication] that works for a lot of people doesn’t work in them.”

    • “What works best in a certain population doesn’t work in some populations, like African American [patients].”

  • Risks

    • “…if the results are not accurate for a patient…you are prescribing something you think is going to work but it doesn’t.”

    • “How much research has been done on it, and is it really cost effective?”

    • “I would need to see efficacy and better treatment after. I would need to see better health in patients who have pharmacogenetic testing done.”

    • “We’re like putting a patient in a certain bracket, so it’s kinda labeling them in a certain way. I do not know if it’ll be used against them or for them.”

    • “…I don’t even think…this population has an understanding of what this is required for.”

    • “If [patients] have to pay out-of-pocket, I think that would be a big stop.”

2. Is pharmacogenomic testing feasible in daily practice?
  • “It’s like an extra step…from what we generally do.”

  • “It’s not a bad idea to include it in your annual work-up.”

  • “I think it would be awesome to start right away.”

3. Should FM be the “gate-keeper” to pharmacogenomic testing?
  • “Primary care…should be trained…because we’re seeing all kinds of patients and we’re the gate-keeper so we should know what’s going on with everything we have.”

  • “We are simultaneous efforts of all the different specialties together.”

4. What needs to be addressed in FM residency training curriculums for successful implementation of pharmacogenomic services?
  • “I want a break-up of how this whole process works and…how I’m [going to] change medication.”

  • “I don’t know that much about it. But if I do my research on it I think I’ll feel more comfortable with it.”

  • “If attending [physicians] start using it, then probably that would force me to use it.”

  • “Pharmacists…have the training; I think you need the knowledge of…pharmacy behind you.”

  • “We need more education, more awareness to integrate it into our day to day…we should have more formal didactics.”